Vanguard Capital Management
CDLX icon

Vanguard Capital Management’s Cardlytics CDLX Stock Holding History

Vanguard Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
218,612
+12,275
+6% +$91.8K ﹤0.01% 3596
2026
Q1 		$2.17M Buy
+206,337
New +$2.01M ﹤0.01% 3338

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's CDLX Position: Q2 2026 in Review

Vanguard Capital Management increased its Cardlytics (CDLX) stake by 5.9% in Q2 2026, buying an estimated $91.8K and bringing the position to 218,612 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #3596.

Vanguard Capital Management first reported a position in CDLX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.17M in Q1 2026. 41 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

  • Vanguard Capital Management held 218,612 shares of Cardlytics worth $982K as of Q2 2026.
  • Vanguard Capital Management bought 12,275 Cardlytics shares in Q2 2026, an estimated $91.8K.
  • Cardlytics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3596 holding.
  • Vanguard Capital Management first reported a position in Cardlytics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Cardlytics position peaked at $2.17M in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.